Sanofi’s Dupixent Is Bucking Lockdown Trend, For Now
Physicians Adopting Telemedicine At Speed
Its emerging flagship drug maintained rapid growth in Q1, but a longer lockdown will hit all competitors’ new prescriptions.
You may also be interested in...
While not promising the fastest development time that the world craves, the combined experience and scale of the two vaccine giants bodes well.
The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.
The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.